The emergence of SARS-CoV-2 triggering the COVID-19 pandemic ranks as arguably the
greatest medical emergency of the last century. COVID-19 has highlighted health disparities …

Objectives The prevalence and clinical outcomes of COVID-19 in patients with autoimmune
diseases who are frequently treated with disease modifying therapies remains poorly …

Objectives COVID-19 outcomes in people with rheumatic diseases remain poorly
understood. The aim was to examine demographic and clinical factors associated with …

As the world navigates the coronavirus disease 2019 (COVID-19) pandemic, there is a
growing need to assess its impact in patients with autoimmune rheumatic diseases, such as …

Purpose To assess efficacy and safety of chloroquine (CQ)/hydroxychloroquine (HCQ) for
treatment or prophylaxis of COVID-19 in adult humans. Materials and methods MEDLINE …

Hydroxychloroquine, initially used as an antimalarial, is used as an immunomodulatory and
anti-inflammatory agent for the management of autoimmune and rheumatic diseases such …

Objectives To evaluate risk factors associated with unfavourable outcomes: emergency care,
hospitalisation, admission to intensive care unit (ICU), mechanical ventilation and death in …

Objective To characterize patients with systemic lupus erythematosus (SLE) affected by
coronavirus disease 2019 (COVID‐19) and to analyze associations of comorbidities and …

Introduction Several months into the COVID-19 pandemic, safe and effective treatments
against this global health disaster have yet to be identified. Clinical research trials around …

Background: Patients with systemic lupus erythematosus (SLE) have an increased risk of
infections due to impaired immune functions, disease activity, and treatment. This study …